title: Implementation of a Hemostatic and Antithrombotic Stewardship program.
abstract: Hemostatic and antithrombotic (HAT) agents are high risk, high cost products. They require close monitoring and dose titration to adequately treat or prevent thrombosis while avoiding bleeding events. Incorporating the principles of inpatient anticoagulation management service into a stewardship program not only improves outcomes and decreases cost, but also improves transitions of care, exposes gaps in therapy management, and leads to the development of institution specific protocols and guidelines. We implemented a HAT Stewardship to provide real time clinical surveillance and management of these agents in an effort to optimize appropriate use, decrease serious adverse events, and minimize costs. The stewardship is staffed daily by an interdisciplinary team comprised of a pharmacist, hematology attending, and medical director. The stewardship focuses on (1) management of heparin-induced thrombocytopenia (HIT), (2) management of patients with Hemophilia A/B with inhibitors and acquired Factor VIII deficiency due to inhibitors, (3) oversight of anticoagulation in patients on extracorporeal membrane oxygenation and (4) assistance with anticoagulation management for patients with mechanical cardiac assist devices. Through implementation of this service, we have been able to demonstrate improved patient care and a positive economic impact exceeding the cost of this program by almost sixfold. Other centers should consider instituting a HAT Stewardship to maximize patient outcomes and minimize adverse events.
authors: Department of Pharmacy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors: David P
authors: DP
authors: Reardon
authors: Julie K
authors: JK
authors: Atay
authors: Stanley W
authors: SW
authors: Ashley
authors: William W
authors: WW
authors: Churchill
authors: Nancy
authors: N
authors: Berliner
authors: Jean M
authors: JM
authors: Connors
mesh_terms: D003365:Costs and Cost Analysis; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000191:economics*; D006467:Hemophilia A / Q000188:drug therapy / Q000191:economics*; D002836:Hemophilia B / Q000188:drug therapy / Q000191:economics*; D006490:Hemostatics / Q000008:administration & dosage / Q000191:economics*; D006801:Humans; D008297:Male; D013921:Thrombocytopenia / Q000188:drug therapy / Q000191:economics*
chemical_list: D005343:Fibrinolytic Agents; D006490:Hemostatics